Market capitalization | $1.55m |
Enterprise Value | $44.33m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.28 |
P/S ratio (TTM) P/S ratio | 0.11 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -54.89% |
Revenue (TTM) Revenue | $13.53m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
3 Analysts have issued a Codex DNA Inc forecast:
3 Analysts have issued a Codex DNA Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 14 14 |
55%
55%
|
|
Gross Profit | 2.98 2.98 |
82%
82%
|
|
EBITDA | -26 -26 |
21%
21%
|
EBIT (Operating Income) EBIT | -30 -30 |
18%
18%
|
Net Profit | -46 -46 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Codex DNA, Inc. engages in research and development of genomic tools for biomedical and industrial applications. It offers BioXp 3200 system and Gibson assembly reagents. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Eric Esser |
Employees | 147 |
Founded | 2011 |
Website | telesisbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.